RACQ

Race Oncology is a clinical-stage biopharmaceutical company focused on developing Zantrene (bisantrene dihydrochloride), a potent inhibitor of the Fat mass and obesity-associated (FTO) protein. Zantrene is a small molecule drug with a long clinical history, originally developed as a chemotherapy agent, which Race is now repurposing for its unique ability to target FTO, a key driver in various cancers. The company's strategy involves exploring Zantrene's potential as both a low-intensity therapy for acute myeloid leukemia (AML) and as a cardioprotective chemotherapy agent in solid tumors. Race Oncology is currently conducting multiple clinical trials to validate Zantrene's efficacy in treating FTO-driven cancers and protecting the heart from chemotherapy-induced damage. By leveraging Zantrene's dual mechanism of action, the company aims to provide safer and more effective treatment options for patients with high-unmet-need cancers.